SC castigates Centre over medicine overpricing, asks 'can you justify this loot'

The Supreme Court criticized the Centre for allowing very large differences between what medicines cost retailers and what patients pay as the maximum retail price. The bench questioned whether manufacturers should be allowed to “run amok” and whether the government could justify such markups. It also challenged the National Pharmaceutical Pricing Authority, or NPPA, saying it seemed “totally defunct.”

The court cited a medicine bought by a retailer for ₹15 but carrying an MRP of ₹250. It also referred to an injection available to a distributor for ₹11,000 but sold by a hospital for ₹1.30 lakh. These examples showed how prices can rise across the supply chain.

The Centre defended a calibrated approach and said Indian medicine prices were among the world’s lowest. The court remained concerned that patients lack bargaining power and reserved its verdict on petitions seeking stronger price controls and generic prescribing.

The maximum retail price, or MRP, is the highest printed price at which a medicine is meant to be sold to consumers. The price to retailer, or PTR, is the amount charged when the retailer buys the medicine from a supplier. It is therefore normally below the MRP.

A trade margin is the difference between the selling price at one stage and the buying price at that stage, usually expressed as a percentage. Margins can exist for distributors, retailers, hospitals, or other sellers. The article focuses on the gap between PTR and MRP, rather than defining every margin separately.

The distinction matters because a low PTR does not guarantee a low patient bill. The court cited a medicine priced at ₹15 to retailers but carrying an MRP of ₹250. It also discussed a trade-margin cap of 30 per cent for anti-cancer drugs and questioned why similar limits could not cover all medicines.

The article describes medicine price gaps as potentially reaching 300 per cent, 400 per cent, or more. That wording shows the court was concerned about very large markups between the price paid by a retailer and the medicine’s maximum retail price. The gap is not presented as a small commercial adjustment.

The clearest example was a medicine with a ₹15 price to the retailer and an MRP of ₹250. That is a difference of ₹235 between the two stated prices. The court also cited a saline drip costing ₹11 but selling in the market for ₹270. These examples illustrate how prices can multiply before reaching patients.

The scale matters because patients often cannot negotiate or delay treatment. The Centre said India has competitive drug markets and some of the world’s lowest medicine prices. The court nevertheless asked where such large differences go and what justifies them, while considering stronger trade-margin controls.

The National Pharmaceutical Pricing Authority, or NPPA, was constituted as an independent regulator for drug pricing. Its purpose is to help ensure that medicines remain available and accessible at affordable prices. In practice, that means monitoring or applying the government’s medicine-pricing framework rather than leaving every price entirely to commercial decisions.

The Supreme Court questioned whether the NPPA was fulfilling that role. The bench described it as seemingly “totally defunct” and said the public appeared to be waiting for benefits that had not arrived. The court’s concern followed examples of very large differences between retailer prices, MRPs, and hospital charges.

The article does not report a new ruling against the NPPA. Instead, the court reserved its verdict on petitions seeking stricter price control and action against alleged overpricing. The Centre defended its wider policy and pointed to a 30 per cent trade-margin cap for anti-cancer drugs, expected to save patients about ₹2,500 crore annually.

When hospitals, retailers, or manufacturers add very large markups, patients face higher bills for medicines they may urgently need. The problem is especially serious because patients often cannot bargain, compare suppliers, or postpone treatment. The Supreme Court stressed that patients have little bargaining power and may have to pay exorbitant prices.

The article gives a stark example involving cancer treatment. An injection available to a medical distributor for ₹11,000 was charged at ₹1.30 lakh by a hospital for the distributor’s wife. The court also mentioned a saline drip whose actual cost was ₹11 but whose market price was ₹270. These differences show how charges can accumulate or expand between supply stages.

The immediate consequence is heavier financial pressure on patients and families. The Centre said its anti-cancer margin cap could save patients about ₹2,500 crore annually. The court is considering whether broader controls are needed, while warning that commerce should not outweigh patients’ lives.

Governments may regulate medicine prices more closely because treatment can be essential, urgent, and difficult to replace. A patient may need a particular drug and may have little ability to delay purchase, compare prices, or negotiate. The Supreme Court highlighted this lack of bargaining power when it questioned very large gaps between medicine costs and patient charges.

Ordinary commercial markets often rely more heavily on competition and consumer choice. The Centre argued that India has many pharmaceutical companies in each drug segment, creating competition and some of the lowest prices in the world. The court responded that competition alone may not protect patients when they must pay an exorbitant price for treatment.

The article presents regulation as a balance between affordability and the pharmaceutical industry’s growth. The Centre favored a calibrated approach and capped anti-cancer trade margins at 30 per cent of MRP. The court asked why similar limits could not apply more widely and said patients’ lives should not be weighed against commerce.

A medicine usually moves through several hands before reaching a patient. Manufacturers set an initial selling price and may include their margin. Distributors and retailers then buy, transport, store, and resell it, adding their own charges or margins. Hospitals may separately purchase medicines and bill patients. The patient ultimately pays the final amount.

The article shows why each stage matters. A medicine with a ₹15 price to the retailer carried an MRP of ₹250. In another example, an injection available to a distributor for ₹11,000 was billed by a hospital at ₹1.30 lakh. These figures do not assign equal blame, but they show that prices can change sharply between supply stages.

Government and the NPPA have a different responsibility: setting, applying, or enforcing pricing rules. The Centre capped anti-cancer trade margins at 30 per cent of MRP. The Supreme Court is considering whether stronger controls should cover other medicines, while the petitions also seek action against alleged unfair practices and generic-prescribing failures.